FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fischer Medical Ventures filed the Q3FY26 Monitoring Agency Report (by Infomerics Valuation and Rating) on utilisation of funds from its Rs. 358.46 crore preferential issue of equity shares and convertible warrants. The company had allotted 1.03 crore equity shares at Rs. 234 each (Rs. 241.05 crore) and received 25% application money on 50.17 lakh warrants (Rs. 29.35 crore), totalling Rs. 270.40 crore subscribed. All Rs. 270.40 crore received has been fully utilised — Rs. 250.41 crore for growth objectives (investments in wholly-owned subsidiaries in imaging technologies and preventive healthcare) and Rs. 19.99 crore for general corporate purposes. The Monitoring Agency reported no deviation from the stated objects, no delay in implementation, and no adverse events. The issue was not fully subscribed, so cost heads were slightly revised downward (Growth from Rs. 272.71 crore to Rs. 268.84 crore; GCP from Rs. 90.90 crore to Rs. 89.61 crore).
This is a routine regulatory compliance filing and is largely neutral for shareholders. It confirms that all funds raised have been deployed as promised, with no misuse or diversion, though the issue was undersubscribed (Rs. 270.40 crore received vs Rs. 363.61 crore planned). Investors should note that a balance of Rs. 88.06 crore from warrant conversions is still pending within the 18-month exercise period, which could bring in additional capital if exercised.